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Sleep-Disordered Breathing Is Increased in Obese
Adolescents with Craniopharyngioma Compared
with Obese Controls
Clodagh S. O’Gorman, Judith Simoneau-Roy, Paul Pencharz, Jamie MacFarlane,
Ian MacLusky, Indra Narang, Khosrow Adeli, Denis Daneman, and Jill Hamilton*
Context: Retrospective studies suggest that adolescents with craniopharygnioma and hypotha-
lamic obesity have increased sleep-disordered breathing (SDB).
Objectives: The objectives of this studywere to compare the prevalence of SDB in adolescentswith
craniopharyngioma-related obesity compared with body mass index (BMI)-matched controls and
to explore possible relationships between SDB, insulin resistance, and adipocytokines.
Design: This was a cross-sectional study of obese craniopharyngioma and obese control adolescents.
Setting: Subjects were evaluated in the clinical investigation unit at the Hospital for Sick Children,
Toronto.
Patients: Fifteen patients with craniopharyngioma-related obesity and 15 BMI-matched controls
were recruited and tested.
Interventions: Each subject underwent fasting bloodwork, frequent sampled iv glucose tolerance
test, polysomnography, and abdominal magnetic resonance imaging with calculation of visceral
and sc adipose tissue.
Main Outcome Measures: Main measures included insulin sensitivity, sleep efficiency, and
fragmentation.
Results: Insulin sensitivitywas lower incraniopharyngiomasubjects comparedwithcontrol subjects
(0.96! 0.34 vs. 1.67! 0.7, P" 0.01). Sleep-onset latency (19.3! 27.8 vs. 31.9! 23.4, P" 0.03) and
oxygen saturations (rapid eye movement sleep: 89.0! 5.1 vs. 94.2! 2.3, P# 0.001; non-rapid eye
movement sleep: 88.4!5.6vs.94.3!1.5,P#0.001)were lower in craniopharyngioma.Obstructive
apnea-hypopnea index (OAHI) (7.5! 9.0 vs. 1.5! 1.5, P" 0.03) was higher in craniopharyngioma.
Respiratory distress index and OAHI correlated negatively with adiponectin concentrations (r "
$0.61, P" 0.03, r"$0.71, P" 0.006, respectively) in craniopharyngioma. Onmultiple regression,
TNF-! and craniopharyngioma were independent positive predictors of sleep-onset latency and
adiponectin and craniopharyngioma were significant predictors (negative and positive, respec-
tively) of OAHI.
Conclusions: SDB is increased in adolescents with craniopharyngioma-related obesity compared
with BMI-matched controls. Routine polysomnography should be considered in obese patients
with craniopharyngioma and appropriate treatment initiated. (J Clin Endocrinol Metab 95:
2211–2218, 2010)
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in U.S.A.
Copyright © 2010 by The Endocrine Society
doi: 10.1210/jc.2009-2003 Received September 18, 2009. Accepted February 26, 2010.
First Published Online March 23, 2010
* Author Affiliations are shown at the bottom of the next page.
Abbreviations: BMI, Bodymass index; CAI, central apnea index; CPAP, continuous positive
airway pressure; CV, coefficient of variation; FSIGT, insulin-modified frequent sampling iv
glucose tolerance test; MRI, magnetic resonance imaging; NREM, non-rapid eye move-
ment; OAHI, obstructive apnea hypopnea index; OSA, obstructive sleep apnea; PSG, poly-
somnography; RDI, respiratorydisturbance index; REM, rapideyemovement; SaO2,oxygen
saturations; SAT, sc adipose tissue volume; SDB, sleep-disordered breathing; SDS, SD score;
Si, insulin sensitivity; SOL, sleep onset latency; TST, total sleep time; VAT, visceral adipose
tissue volume; WC, waist circumference.
O R I G I N A L A R T I C L E
E n d o c r i n e C a r e
J Clin Endocrinol Metab, May 2010, 95(5):2211–2218 jcem.endojournals.org 2211
Sleep-disordered breathing (SDB), specifically obstruc-tive sleep apnea (OSA) is common, occurring in
1–4% of healthy children (1). Estimates of the prevalence
ofOSA in obese children vary from13 to 60%, depending
on the definitions of OSA and obesity (2). Evidence sug-
gests that insulin resistance is positively associated with
SDB inadolescents (3).Apediatric study showedapositive
correlationbetween fasting insulin and the respiratorydis-
turbance index (RDI), a measure of sleep fragmentation
(4). Furthermore, a retrospective review suggested an as-
sociation between lower total sleep time (TST) and insulin
resistance (5).
Sleep is complex and its physiological regulation ismul-
tifactorial. The cytokines, IL-6 and TNF!, are involved in
physiological sleep regulation and correlate positively
with the obstructive apnea-hypopnea index (OAHI; a
measure of sleep fragmentation) in obese adults (6). Ad-
ministration of exogenous IL-6 to adults results in in-
creased sleepiness and fatigue (7). IL-6 and TNF-! are
elevated in adults with either SDB or obesity (8). The adi-
pocyte-derived proteins (adipokines) leptin and adiponec-
tin play a role in energy homeostasis and insulin sensitivity
(Si) (9). Leptin is secreted in proportion to adipose mass
and is elevated in obesity. However, hyperleptinemia fails
to suppress appetite or increase metabolic rates, presum-
ably due to central nervous system leptin resistance (9).
Leptin is increased in pediatric OSA, independent of the
body mass index (BMI) (10). Adiponectin, an insulin sen-
sitizer, is decreased in obesity (9). To date, adiponectin
levels have not been correlatedwith SDB independently of
obesity (10, 11). Furthermore, sleep abnormalities coexist
frequently with cardiovascular disease, may activate path-
ways that causeoraggravate cardiovasculardamage,ormay
cause resistance to conventional antiobesity therapies (12).
A primary hypothalamic function is to regulate the
sleep-wake cycle. Hypothalamic damage, complicated by
obesity, temperature, and sleep dysregulation and pitu-
itary hormone deficiency, occurs commonly after treat-
ment for pituitary or hypothalamic tumors, including cra-
niopharyngioma (13). The literature evaluating SDB in
this population is sparse. One questionnaire-based study
reported frequent sleep abnormalities in craniopharyngi-
oma (14). A prospective study in pediatric craniopharyn-
gioma included three patients and identified increased
SDB by questionnaire and polysomnography (PSG) (15).
Our clinical experience is that patients with craniophar-
yngioma and hypothalamic obesity complain commonly
of specific disturbed sleeping patterns, including difficulty
falling asleep, nocturnal waking, and extreme sleepiness
during the afternoon. Furthermore, adolescents with cra-
niopharyngioma are at increased risk for metabolic ab-
normalities, including dyslipidemia, increased insulin re-
sistance, and the metabolic syndrome (16, 17), which
could exacerbate or contribute to SDB. Given the hypo-
thalamic disturbances in craniopharyngiomapatients, it is
possible that they exhibit more SDB than otherwise
healthy children of similar weight.
Aims
The aims of this study were to compare incidence of
SDB and explore the relationships between SDB, Si, and
inflammatory cytokines in adolescents with cranio-
pharyngioma and hypothalamic obesity and age- and
BMI-matched controls. We hypothesized that patients
with craniopharyngioma would have more SDB than
BMI-matched controls.
Methodology
Our institutional ethics review board approved this pro-
tocol. Inclusion criteria for craniopharyngioma subjects
included craniopharyngioma diagnosed at least 1 yr be-
fore study participation and adequate replacement of all
pituitary hormone deficiencies. Controls, recruited froma
weight management clinic, were otherwise healthy and
age,BMI, andgendermatched to craniopharyngioma sub-
jects. Exclusion criteria included: use of medications that
might alter lipid levels, Si, or adiposity; respiratory ab-
normalities that might preclude interpretation of sleep
studies; or known sleep abnormalities. Craniopharyngi-
oma subjects took their usual hormone replacement med-
ications before study participation.
At study initiation, each subject was admitted to the
clinical research center for physical examination with an-
thropometrics, performed by a single examiner. Height
and weight were measured using a wall-mounted stadio-
meter and a calibrated scale, respectively. BMI was cal-
culated as weight (kilograms)/height2 (square meters).
BMI SD scores (SDS)were calculated using a program from
the Centers for Disease Control and Prevention web site
(18). Waist circumference SDS was calculated using pub-
lished normal values (19).
Fasting blood samples were taken for baseline labora-
tory evaluation (including glucose, insulin, leptin, adi-
ponectin, IL-6, TNF!). Insulin-modified frequent sam-
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pling iv glucose tolerance test (FSIGT) was performed
after an overnight fast (20–22). Via an iv antecubital can-
nula, 0.3 g/kg of 25% dextrose, followed 20 min later by
0.03 U/kg of regular insulin (Humulin R; Eli Lilly, India-
napolis, IN), was injected. Thirty-four blood samples for
glucose and insulin were taken over 3 h from the con-
tralateral arm.Themathematicalmodel of Bergman (min-
imal model) (23) using MINMOD computer software
(MINMOD Millennium, Version 5.18, MINMOD, Inc.,
Pasadena, CA) and data fromFSIGTwas used to calculate
Si (minutes$1 per milliunit$1 per milliliter$1).
During a second admission, each subject had overnight
PSG for evaluation of sleep abnormalities, supervised by
trained pediatric sleep technologists in the sleep medicine
laboratory. Every PSGwasperformed in aquiet, darkened
room,without the use of sleep-inducingmedications,with
one parent present, and was interpreted by a single pedi-
atric sleep medicine physician.
All PSGs were conducted and scored according to the
American Academy of SleepMedicine manual for scoring
sleep and associated events (24) with a computerized sys-
tem (XL-TEK, Oakville, Ontario, Canada). A standard
overnight PSG included a 4-lead electroencephalogram
(C3, C4, O1, and O2), two bilateral electrooculogram
leads referenced to A1 or A2, and one submental and two
tibial electromyograms. Respiratory measurements in-
cluded chest wall and abdominal movement using induc-
tance pneumography; airflow using a nasal cannula con-
nected to a nasal pressure airflow; oxygen saturation
(SaO2); and transcutaneous carbon dioxide measure-
ments. Video and audio recordingswere obtained for each
study. Sleep architecture was assessed by standard tech-
niques (25). Information obtained from each PSG in-
cluded sleep onset latency (SOL) and rapid eye movement
sleep (REM)-onset latency, TST, sleep efficiency, time
spent in each sleep stage (minutes and percentage), and the
number of arousals. Recorded respiratory data included
counts and indices of the following events: obstructive
apneas and hypopneas (OAHI), central apneas [central
apnea index (CAI)], and mixed apneas recorded in non-
REM (NREM) sleep, REM sleep, and total sleep.
An obstructive apnea event was scored when airflow
dropped at least 90% from baseline with chest and/or
abdominal motion throughout the entire event, the dura-
tion of which was at least a minimum of two baseline
breaths. An obstructive hypopnea event was scored when
airflow dropped at least 50% from baseline, the duration
of which was at least a minimum of two baseline breaths.
The event must have been accompanied by one of the fol-
lowing: 1) 3% or greater drop in SaO2; 2) an arousal; or
3) an awakening (24). A central apnea was defined as a
cessation of airflow with an absence of respiratory and
abdominal effort for 20 sec or longer or of the duration
of two prior baseline breaths in which case the event
must be accompanied by one of the following: 1) 3% or
greater drop in oxygen saturation; 2) an arousal; or
3) an awakening.
Definitions
OSA severity was graded using current clinically ac-
cepted criteria according to the OAHI, the number of ob-
structive apneas, and obstructive hypopneas per hour dur-
ing sleep. OAHI less than 1.5 was normal. OSA was
defined as: mild, OAHI greater than 1.5–5; moderate,
greater than 5–10; and severe, greater than 10. CAI was
defined as the number of central apneas per hour during
sleep; more than 1.0 per hour was abnormal. SOL was
defined as the length of time in minutes from lights out to
the first epoch of sleep. TST was defined as the sum of all
the minutes spent in all stages of sleep or the total time in
bed minus all time spent awake during the study. Sleep
efficiency was defined as TST divided by the time in bed
multiplied by 100. RDIwas defined as the total number of
apneas, hypopneas, and arousals per hour. The arousal
index was defined as the number of arousals per hour.
Sleep fragmentation is associated with a high arousal in-
dex, increase in wakefulness during the night, and an in-
crease in stage 1 sleep (typically 5–10%).
Visceral and sc adipose tissue volumes (VAT and SAT)
were measured in each subject using abdominal magnetic
resonance imaging (MRI) (General Electric Twin Speed
EXCITETM III 12.0 1.5 Tesla; GE Healthcare, Milwaukee
WI), using previously published methodology (26).
Biochemical analyses
Insulin was measured by chemiluminescence using the
Immulite 2500 [Siemens,Melvern, PA; range of assay 15–
2165 pmol/liter, intra- and interassay coefficient of vari-
ation (CV) # 7.6%]. Leptin and adiponectin were mea-
sured by ELISA (Diagnostics Systems Laboratories Inc.,
Webster, TX; range 0.1–50.0 ng/ml; interassay CV 1.5–
6.2%; and Linco Research Inc., St. Charles, MO; range
1–100 mg/liter; CV 2.4–8.4%, respectively). IL-6 and
TNF! were measured using chemiluminescence (Siemens
Immulite 1000; range: 2–1000 pg/ml; CV # 7.5%; and
range 1.7–1000 pg/ml; CV # 6.5%, respectively).
Statistical analysis
Statistical analysis was performed using SAS software
(SAS version 8.2, 1999; Cary, NC). Continuous variables
were expressed asmeans! SDs.Categorical variableswere
expressed as frequencies. Comparisons between groups
were performed using the Fisher’s exact test and "2 anal-
ysis for categorical parameters and Student’s t test for con-
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tinuous variables, with Bonferroni correction formultiple
comparisons. Data distribution was first assessed using
simple measures of central tendencies and completed by
performing Shapiro-Wilk’s test for normality. Log trans-
formations were performed on nonnormative variables
and then compared by Student’s t test. Pearson correlation
analyses were performed between measures of SDB and
measures of Si and cytokines.Multiple regression analysis
was performed using factors significant on univariate re-
gression, with only three variables entered (due to the
small number of subjects).
Results
Of 43 children who had surgery for craniopharyngioma
and were followed up at our institution, 22 developed
postoperative obesity, defined as BMI greater than the
95th percentile for age and gender (13). Sixteen (77.3%)
consented to participate; one was subsequently excluded
after starting metformin therapy. Therefore, we enrolled
15 children aged 10–21 yr. No subject had received ra-
diotherapy. We also enrolled 15 age-, sex-, and BMI-
matched children with exogenous obesity. However, cra-
niopharyngioma children had higher waist circumference
(WC) and WC-SDS than controls (Table 1).
Craniopharyngioma subjects had multiple pituitary
hormonal insufficiencies but were receiving adequate re-
placement therapies including: 14 of 15 treated with des-
mopressin for diabetes insipidus; 14 of 15 treated with
hydrocortisone (dose range 8–12 mg/m2 ! d); 14 of 15
treated with levothyroxine (free T4 levels on treatment
14.5! 2.6 pmol/liter); and eight of 15 treated with sc GH
(all formore than 12months). Craniopharyngioma subjects
were treatedwithGHif theywerebothGHdeficientandhad
growth failure and with sex steroid replacement therapy if
they had hypogonadism biochemically and clinically. Of
seven of 15 patients GHuntreated, five of seven had normal
growth without GH, and two of seven had completed their
growth and were postpubertal at the time of diagnosis with
craniopharyngioma.Fivepatientsreceivedhormonereplace-
ment therapy for hypogonadotrophic hypogonadism. No
control was receiving medication.
The duration of follow-up from diagnosis of cranio-
pharyngioma to assessment was 4.9 ! 3.0 yr and corre-
lated positively with both BMI (r " 0.58, P " 0.02) and
BMI SDS (r " 0.64, P # 0.01). All craniopharyngioma
subjects had evidence of hypothalamic damage on neu-
roimaging after tumor resection. Time between each of
the two visits was 4.6 months (range 0–11) in the cra-
niopharyngioma group and 3.0 months (range 0–8) in
controls.
After their initial PSG, two craniopharyngioma sub-
jects required initiation of nocturnal continuous posi-
tive airway pressure (CPAP) therapy. Their untreated
PSG results are reported here. No control required
CPAP initiation.
Si from FSIGT data was significantly lower in cranio-
pharyngioma subjects compared with controls (0.96 !
0.34 vs. 1.67 ! 0.7, P " 0.01) (Table 1). TNF! was sta-
tistically higher in craniopharyngioma compared with
controls, with no difference in IL-6 (Table 1). On abdom-
inalMRI, there were no differences between groups in the
volumes of SAT (craniopharyngioma 501.2! 155.4, con-
trols 480.3 ! 185.5, P " 0.77), VAT (craniopharyngi-
oma, 85.1 ! 40.5; controls, 67.5 ! 29.5, P " 0.25) or
TABLE 1. Comparison of patient demographics and biochemical measures between groups
Demographics Craniopharyngioma Control P value
Age (yr) 15.5 ! 4.0 15.1 ! 2.3 0.77
Sex (females, males) 8, 7 10, 5 0.72
Height (cm) 159.5 ! 14.6 165.0 ! 8.8 0.22
Weight (kg) 91.2 ! 29.3 91.9 ! 18.0 0.94
BMI (kg/m2) 35.2 ! 8.0 33.5 ! 4.9 0.49
BMI SDS 2.2 ! 14.6 2.1 ! 0.3 0.53
Tanner stage (I–V) (median) 3 4 0.07
SAT volume (cm3) 501.2 ! 155.4 480.3 ! 185.5 0.77
VAT volume (cm3) 85.1 ! 40.5 67.5 ! 29.5 0.25
VAT to SAT ratio 0.18 ! 0.08 0.16 ! 0.09 0.38
WC (cm) 122.1 ! 27.5 102.2 ! 11.5 0.02
WC SDS 7.3 ! 3.0 5.1 ! 1.8 0.04
Biochemical measures
Adiponectin (mg/liter) 10.6 ! 5.4 8.4 ! 1.8 0.13
Leptin (ng/ml) 116.7 ! 93.9 99.6 ! 69.6 0.47
IL-6 (pg/ml) 3.0 ! 1.2 3.1 ! 3.1 0.86
TNF! (pg/ml) 5.8 ! 2.3 3.9 ! 1.4 0.01
Si (FSIGT) (%10$4/min$1 ! #IU ! ml) 0.96 ! 0.34 1.67 ! 0.70 0.01
Data given are means ! SD, except where indicated.
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VAT to SAT ratios (craniopharyngioma, 0.18 ! 0.08;
controls, 0.16 ! 0.09, P " 0.38).
Sleep indices (Table 2)
SOLwas significantly lower in craniopharyngiomaand
TST trended toward longer, suggesting that craniophar-
yngioma subjects fall asleep quicker and remain asleep
longer. OAHI was significantly higher in craniopharyn-
gioma subjects. All 13 obese controls had either normal or
mild OAHI (i.e. fewer than five episodes per hour) com-
pared with seven of 13 craniopharyngioma subjects. Of
the remaining six craniopharyngioma subjects, two had
moderate and four had severe OAHI. There was no sig-
nificant difference in RDI, percentage time in slow wave
sleep, or sleep efficiency index between groups. Mean
SaO2 was lower in craniopharyngioma than control in
both REM and NREM sleep. Minimum SaO2 was lower
in craniopharyngioma thancontrols.Craniopharyngioma
and control subjects spent similar times in stage 1 sleep,
but craniopharyngioma subjects had significantly shorter
percentage of time in stage 2 sleep.
Whereas there were no differences found between sub-
jects with craniopharyngioma who were GH treated or
GH untreated, in OAHI (GH treated, 3.9 ! 5.6; GH un-
treated, 13.3 ! 11.0, P " 0.17) or RDI (GH treated,
14.0! 10.5; GH untreated, 24.8! 16.9, P" 0.22), with
the relatively small number of subjects, it was unlikely
such a difference could be identified.
SOL correlated positively with Si (r" 0.79, P" 0.03)
and leptin (r" 0.63 P" 0.02) in the craniopharyngioma
group. SOL showed no significant correlations in the con-
trol group. TST correlated positively with IL-6 (r" 0.55,
P # 0.01) in the control group. OAHI correlated nega-
tively with adiponectin and WC in craniopharyngioma
subjects (r " $0.7, P " 0.01, and r " 0.7, P " 0.03,
respectively) (Fig. 1) but showedno significant correlation
in controls. RDI correlated negatively with adiponectin in
craniopharyngioma subjects (r " $0.61, P " 0.03) (Fig.
1) but did not show significant correlations in controls. In
craniopharyngiomasubjects, after controlling forWCand
WC-SDS, respectively, adiponectin correlated well with
each of OAHI (r " $0.70, P " 0.006; r " $0.71, P "
0.007), CAI (r"$0.92, P" 0.06; r"$0.85, P" 0.07),
and RDI (r"$0.076, P" 0.008; r"$0.74, P" 0.009).
TNF! predicted negatively and craniopharyngioma
predicted positively SOL (t"$0.32, P# 0.001; t" 1.0,
P" 0.02, respectively). Adiponectin predicted negatively
and craniopharyngioma predicted positively OAHI (t "
$4.5, P# 0.001; t" 4.4, P# 0.001, respectively). Si was
not a significant predictor on multiple regression.
Discussion
Our data suggest that adolescents with craniopharyngio-
ma-related obesity have more SDB than obese, otherwise
healthy, BMI-matched adolescents. This is evidenced by
increased OAHI and a trend toward increased CAI in the
craniopharyngioma group, suggesting more sleep frag-
mentation and less sleep efficiency. They also exhibit de-
creasedSOLanda trend toward increasedTST, suggesting
FIG. 1. A, Plot of adiponectin against OAHI. B, Plot of adiponectin
against RDI.
TABLE 2. Sleep measures
Craniopharyngioma Control P value
SOL (min) 19.3 ! 27.8 31.9 ! 23.4 0.03
TST (min) 392.6 ! 59.3 350.4 ! 54.1 0.08
Sleep efficiency (%) 82.7 ! 14.9 90.5 ! 11.1 0.83
REM latency (min) 164.3 ! 97.8 136.5 ! 47.1 0.37
Sleep stage 1 (% of TST) 4.6 ! 2.5 4.7 ! 3.3 1.00
Sleep stage 2 (% of TST) 48.7 ! 9.4 57.0 ! 9.7 0.04
Slow wave sleep (% of TST) 28.3 ! 11.0 23.9 ! 5.6 0.10
Sleep REM stage (% of TST) 17.6 ! 5.0 15.0 ! 5.0 0.20
Mean SaO2 (% in REM) 89.0 ! 5.1 94.2 ! 2.3 #0.001
Mean SaO2 (% in NREM) 88.4 ! 5.6 94.3 ! 1.5 #0.001
Minimum SaO2 (%) 86.3 ! 5.9 93.6 ! 2.1 0.0005
Highest CO2 (mm Hg) 50.8 ! 8.1 42.9 ! 13.5 0.10
RDI 18.1 ! 13.8 12.3 ! 7.1 0.38
OAHI 7.5 ! 9.0 1.5 ! 1.5 0.03
CAI 0.99 ! 1.5 0.22 ! 0.31 0.06
Data given are means ! SD.
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more sleepiness in craniopharyngioma subjects. In partic-
ular, obese craniopharyngioma subjects exhibit more ob-
structive episodes and lower SaO2 during both REM and
NREMsleep than BMI-matched controls. These data sug-
gest that the mechanism of obesity, not just the degree of
obesity, may affect SDB. TNF! and diagnosis of cranio-
pharyngioma are independent positive predictors of
shorter SOL. Additionally, lower adiponectin and cranio-
pharyngioma group predict higher OAHI.
To our knowledge, adiponectin levels have not previ-
ously been found to correlate with SDB independently of
BMI or other measures of adiposity. Physiologically, adi-
ponectinpotentiates sensitivity to insulinperipherally.Re-
cently adiponectin receptors have been identified in the
periventricular nuclei and area postrema in mice models,
inwhich their central effects include reduction of body fat,
glucose, and lipids (27). Thus, adiponectinmay play a role
in SDB. IL-6 did not emerge as a significant predictor of
SDB on multiple regression analyses. This is consistent
with recent data suggesting that obesity, not SDB, is the
major risk factor for insulin resistance (28), with a recent
study that foundnodifference in IL-6betweengroupswith
similar BMI but differed in the presence or absence of SDB
(29). We found higher TNF! levels in patients with more
SDB (as measured by lower sleep onset latency.) The in-
terrelationship between TNF! and SDB is complex, and
the cause and direction of the association are unclear (11).
Sleep deprivation alone results in increased TNF! and
IL-6,whereasTNF! is itself ahypnotic (30).BothSDBand
obesity are inflammatory states associated with increased
TNF! levels. One study suggests that TNF! levels are
increased in SDB and that the level of TNF! correlates
positively with both the degree of sleepiness and the se-
verity of hypoxia (31). Our study supports these findings
because we identified a significant positive relationship
between TNF! and shorter SOL in this obese population.
Obesity contributes potentially to SDB via several po-
tential mechanisms. First, both obesity and SDB are sys-
temic inflammatory disorders. Second, impaired Si is as-
sociated with sleep disturbances (3). Third, increased sc
tissue in the neck increases the risk of obstructive sleep
apneas (32). Fourth, increased WC in the craniopharyn-
gioma group, with implied increased intraabdominal fat
accumulation, could also lead to SDB. However, adi-
ponectin, when controlled for WC, still correlated signif-
icantly with measures of SDB, suggesting that factors
other than visceral adiposity mediate alterations in SDB
via Si. It is possible that in patients with craniopharyngi-
oma, adiponectin is affected more by dysregulated insulin
secretion through, for example, increased vagal tone, than
it is affected by visceral adiposity. All four etiologies could
contribute to SDB in patients with hypothalamic obesity.
An additional mechanism that may contribute to SDB in
craniopharyngioma subjects is sleep disturbance and cen-
tral apnea due to hypothalamic damage. Several hypotha-
lamic nuclei, including the suprachiasmatic nuclei (which
control the circadian drive to wakefulness) (33) and the
ventrolateral preoptic nuclei (which control the homeo-
static drive to sleep) (34), are responsible for regulation of
sleep. The circadian rhythm is the result of a complex
interaction between circadian and homeostatic processes
(34). Specifically important in SDB and hypothalamic
damage, three sets of hypothalamic nuclei are situated
close to each other: those involved in sleep and wake reg-
ulation; those responsible for the release of pituitary-con-
trolling releasing hormones; and those that produce and
store hormones released by the posterior pituitary. Thus,
damage to one of these nuclei groups may coexist with
damage to neighboring nuclei.
Our study did not attempt to determine the physiolog-
ical reasons for SDB in craniopharyngioma. Furthermore,
the craniopharyngioma subjects in this study all had hy-
pothalamic damage based on MRI. In subjects with cra-
niopharyngioma but without hypothalamic obesity, the
results of sleep studies may be different. Correlation of
specific areasof hypothalamicdamage to sleepparameters
would be interesting, but the neuroimaging of our cranio-
pharyngioma subjects are not sensitive enough to define
which specific hypothalamic areas and nuclei are affected.
This problem has been acknowledged previously (15). In
the future, however, with advancing neuroimaging tech-
niques, identification of these regions may be easier.
Pituitary hormone deficiencies also potentially in-
creased SDB in craniopharyngioma in this study. Al-
though all craniopharyngioma patients had adequate hor-
mone replacement, there are possibly differences between
prescribed hormone replacement therapies and hormone
levels altered by autoregulation and feedback mecha-
nisms. Also, the close proximity of sleep nuclei and pitu-
itary hormone nuclei implies that damage to both nuclei
groups might occur simultaneously. Further studies
should evaluate this. We did not identify any association
between GH deficiency and SDB. Previous studies have
identified longer TST and less deep sleep in GH-deficient
patients and decrease in TST after GH replacement (35).
Furthermore, GH replacement in GH-deficient individu-
als has been associated with improved qualify of life (36).
It is possible that we did not find any associations because
GH was adequately replaced in many of the craniophar-
yngioma subjects. For those not receiving GH therapy but
who may have been GH deficient, it may have been too
early in their course to pick up major differences in sleep
related to GH deficiency, although there were too few
subjects in our study to realistically examine this question.
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A study of sleep abnormalities in five pediatric patients
with hypothalamic-pituitary obesity (three of five had cra-
niopharyngioma) and five age- but not BMI-matched con-
trols describedmore subjective sleepiness,more inefficient
sleep (as measured by stage 3–4 sleep), and lower mean
sleep length in patients with hypothalamic obesity (15).
This study did not measure Si or adipokines (15). A ret-
rospective case series, in which subjects were not matched
with controls, identified increased TST and decreased
SaO2 in subjects with central nervous system tumors (37).
The worst sleep abnormalities were identified in subjects
with pituitary or hypothalamic abnormalities (37).
The type of central nervous system tumormight impact
the severity of SDB. For example, a study using question-
naire assessments of sleep identified severe sleepiness in
35% of 79 children with craniopharyngioma and 15% of
19 childrenwith pilocytic astrocytomas (14).Noobjective
assessment of sleep abnormalities was performed, and
there was no healthy control group. Another question-
naire study, in an adult population, identified increased
subjective sleepiness and increased snoring in patients
with either craniopharyngioma or nonfunctioningmacro-
adenomas, comparedwith healthy controls (38). Sleep ab-
normalities were not assessed objectively.
To our knowledge, this is the largest study to date ad-
dressing SDB in a pediatric population with craniophar-
yngioma and hypothalamic dysregulation. Furthermore,
our craniopharyngioma and control populations were
age, gender, andBMImatched, suggesting that differences
between the two groups are due to craniopharyngioma
andhypothalamic damage.Additionally,we included cra-
niopharyngioma and control subjects without prior
screening with sleep questionnaires. Sleep questionnaires
have not been found to accurately reflect SDB as detected
by sleep studies assessments (39). However, measure-
ments of neck circumference, which is a validated corre-
late of SDB in adult populations (32), might have helped
to distinguish OSA related to oropharyngeal sc fat depo-
sition fromcentral sleep apneas.Weacknowledge that our
sample size was relatively small. However, craniopharyn-
gioma with hypothalamic dysregulation is a rare disease,
and this is one of the largest studies of this population
to date.
Longitudinal sleep and metabolic studies will be re-
quired to establish the onset, etiology, and causation of
SDB in craniopharyngioma. For example, sleep studies
performed before surgery and the postoperative period of
rapidweight gain (13)might identify the natural course of
this disorder. Craniopharyngioma patients are at in-
creasedof cardiovascular disease (40), and the coexistence
of SDB may further compound this risk. Common path-
ways of inflammation may increase endothelial dysfunc-
tion and cardiovascular risk aswell as impact onSDB (12).
Future studies to include evaluation of early endothelial
dysfunction in relation to other metabolic and sleep pa-
rameters should address this question.
Conclusion
This study demonstrates that SDB is common among
patients with hypothalamic dysregulation and obesity af-
ter craniopharyngioma treatment and that SDB in this
group ismore common than in an age-, gender-, and BMI-
matched population. Two of 15 subjects required inter-
vention with CPAP after the sleep assessment, indicating
an unrecognized sleep disorder.We suggest that clinicians
should consider performing routine PSGs in all patients
with craniopharyngioma and hypothalamic dysregula-
tion. Further multicenter studies will be required to eval-
uate longitudinally the potential effects of SDB treatment
on weight gain, and metabolic parameters.
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